HOME >> MEDICINE >> NEWS
Heart surgery patients receive less aggressive discharge care

DURHAM, N.C. -- Patients who undergo coronary artery bypass surgery are prescribed life-saving medications at discharge significantly less frequently than heart attack patients who receive less invasive angioplasty procedures, according to a new analysis by researchers at the Duke Clinical Research Institute.

These findings are important, the researchers said, because the drugs in question -- aspirin, ACE inhibitors, beta blockers and statins -- have been proven effective by multi-center clinical trials to reduce repeat cardiac events and death and therefore incorporated in established guidelines for care of heart attack patients. The researchers said much room exists for improving the usage rates of these life-saving drugs among all heart patients, including those who received angioplasty.

For example, the Duke team found that 65 percent of angioplasty patients received ACE inhibitors -- a class of blood vessel-relaxing drugs -- compared to only 44 percent of bypass patients. The cholesterol-lowering statins were prescribed for 76 percent of angioplasty patients and 62 percent of bypass patients.

Additionally, the team found in its analysis of data from a national registry of heart attack patients that those who received surgery were much more likely than angioplasty patients to receive diet modification counseling and referrals to cardiac rehabilitation.

The use of discharge medications and behavior modifications, which includes smoking cessation counseling, are officially recommended by the American Heart Association (AHA) and the American College of Cardiology (ACC) as preventive measures against future heart problems and death.

"In general, discharge care given to angioplasty patients is more aggressive and is more consistent with national guidelines than is the discharge care given to the surgical patients," said Duke cardiologist Christopher Dyke, M.D, who presented the results of the
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
8-Nov-2004


Page: 1 2 3

Related medicine news :

1. The European Society of Cardiology launches Women at Heart
2. Heart surgeons publish death rates
3. Heart attack treatment gap may be closing for women
4. The Larry King Cardiac Foundation presents The Changing Face of Heart Disease on Feb. 2
5. Brenner Childrens Hospital named to NIH Pediatric Heart Network
6. Heart patients treated by non-cardiologists less likely to receive medications
7. Heart failure patients treated for diabetes with insulin have increase in mortality
8. New research results: Heart jacket shown to be effective
9. Heart attack, stroke risk overlooked in diabetics
10. Heart arrhythmias easily treated, yet few know risks
11. Donald W. Reynolds Foundation awards UT Southwestern $12 million to continue Dallas Heart Study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heart surgery patients receive less aggressive discharge care

(Date:5/21/2013)... Today, Zane Benefits, Inc. published a ... accounts. Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and http://HRA ... to Zane Benefits’ website, the Affordable Care Act (known ... in 2010 and impacts many areas of health care ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two executives ... Guidance (SBG) will identify which strategies can be most ... high-quality care to the members who are taking them, ... Services, Inc., “How to Manage Specialty Drugs to ... pharmaceuticals are now the main driver for rising prescription ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 While North ... synonymous with comprehensive travel guides. Brunswick Plantation & Golf ... packages that include access to 27 holes of "Top10" ... courses in North Carolina, knowing the Top 10 ... Lodges takes away the overwhelming task of selecting the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Octo ... technology and management consulting solutions to the Federal ... Business Development. In the newly created role, ... all aspects of the firm’s business development function ... proposal management functions, and leading strategies to achieve ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... therapy for patients having severe bouts of chronic obstructive ... days of glucocorticoid treatment with prednisone to treat COPD ... but with fewer chances for adverse side effects, they ... period of treatment was not less effective than 14 ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: